Skip to main content

Table 4 Structures used in protein-ligand and protein-protein pocket analysis

From: Visualisation of variable binding pockets on protein surfaces by probabilistic analysis of related structure sets

Target protein (PDB id of apo structure)

Inhibitor (PDB id)

Protein partner (PDB id)

Bcl-X L )

acyl sulfonamide derivative

Bak

(1LXL)

(1YSI)

(1BXL)

MDM2

benzodiazapine derivative

p53

(1Z1M)

(1T4E)

(1YCR)

Xiap apoptosis inhibitor

naphthalenamide derivative

Caspase 9

Bir3 domain (1F9X)

(1TFQ)

(1NW9)

Xiap apoptosis inhibitor

Smac peptidomimetic

SMAC caspase activator

Bir3 domain (1F9X)

(2JK7)

(1G73)

ZipA

indoloquinolizin inhibitor 1

FtsZ

(1F46)

(1S1J)

(1F47)

HPV11 E2 protein

tetrahydrofuran derivative

HPV11 E1 protein

(1RK6)

(1R6N)

(1TUE) (1R6N)

Interleukin 2

diphenyl derivative

IL2-Receptor

(1M47)

(1M48)

(1Z92)

HIV-1 Integrase

chlorophenyl-dihydroquinolin acetic acid

LEDGF

(3L3U)

(3LPT)

(2B4J)

TNFa subunit A

chromen-4-one derivative

TNFa subunit B

(1TNF)

(2AZ5)

(1TNF)

TNF receptor 1a

thiazolidin-4-one derivative

TNF-beta

(1EXT)

(1FT4)

(1TNR)

MDM4 subunit A

chlorobenzyl-phenyl-imidazol derivative

p53

(3DAB)

(3LBJ)

(3DAB)

  1. Structures used in comparative analyses (detailed in Tables 1 and 2) are taken from the 2P2I database of protein-protein complexes with known inhibitors of the protein-protein interaction. In each case, an ensemble is generated from the apo structure, pockets from this ensemble are analysed and compared with binding sites/interfaces determined from the inhibitor and protein-protein complex structures. In the case of TNF-alpha, the inhibitor disrupts a protein-protein interface in the native trimer, and the apo and protein-protein complex structure files are consequently the same